Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results From Phase 2 Radiant Study Of Remlifanserin For The Treatment Of Alzheimer’S Disease Psychosis

Acadia Pharmaceuticals Inc. NASDAQ:ACAD